Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: Evidence from Asia and around the globe
Donna Shu‐Han Lin, Tzung‐Dau Wang, Peera Buranakitjaroen, et al.
Journal of Clinical Hypertension (2020) Vol. 23, Iss. 3, pp. 556-567
Open Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the Management of Hypertension.
Tzung‐Dau Wang, Chern‐En Chiang, Ting‐Hsing Chao, et al.
PubMed (2022) Vol. 38, Iss. 3, pp. 225-325
Closed Access | Times Cited: 90
Nocturnal Hypertension and Heart Failure: Mechanisms, Evidence, and New Treatments
Kazuomi Kario, Bryan Williams
Hypertension (2021) Vol. 78, Iss. 3, pp. 564-577
Open Access | Times Cited: 63
Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: a randomized, double-blind, multicenter study
Hiromi Rakugi, Kazuomi Kario, Masako Yamaguchi, et al.
Hypertension Research (2022) Vol. 45, Iss. 5, pp. 824-833
Open Access | Times Cited: 56
Seven‐action approaches for the management of hypertension in Asia – The HOPE Asia network
Kazuomi Kario, Yook Chin Chia, Saulat Siddique, et al.
Journal of Clinical Hypertension (2022) Vol. 24, Iss. 3, pp. 213-223
Open Access | Times Cited: 41
Novel pharmacological approaches to lowering blood pressure and managing hypertension
Matthew Sayer, David J. Webb, Neeraj Dhaun
Nature Reviews Cardiology (2025)
Closed Access | Times Cited: 1
Twenty‐Four‐Hour Blood Pressure‐Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double‐Blind Multicenter Study
Kazuomi Kario, Hiromi Rakugi, Daisuke Yarimizu, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 8
Open Access | Times Cited: 17
Angiotensin receptor–neprilysin inhibitors for hypertension—hemodynamic effects and relevance to hypertensive heart disease
Kazuomi Kario, Bryan Williams
Hypertension Research (2022) Vol. 45, Iss. 7, pp. 1097-1110
Closed Access | Times Cited: 22
Latest hypertension research to inform clinical practice in Asia
Kazuomi Kario, Masaki Mogi, Satoshi Hoshide
Hypertension Research (2022) Vol. 45, Iss. 4, pp. 555-572
Open Access | Times Cited: 19
Unique characteristics of Asians with hypertension: what is known and what can be done?
Germaine Loo, Troy Puar, Roger Foo, et al.
Journal of Hypertension (2024) Vol. 42, Iss. 9, pp. 1482-1489
Open Access | Times Cited: 4
Angiotensin Receptor Blocker-Neprilysin Inhibitor for Heart Failure with Reduced Ejection Fraction
Dima Nasrallah, Alaa Abdelhamid, Omar Tluli, et al.
Pharmacological Research (2024) Vol. 204, pp. 107210-107210
Open Access | Times Cited: 4
Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis - A Randomized Controlled Multicenter Study
Lin Li, Weijing Bian, Qun Luo, et al.
Kidney Diseases (2025) Vol. 11, Iss. 1, pp. 206-217
Open Access
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Ji‐Guang Wang
Journal of Geriatric Cardiology (2025) Vol. 22, Iss. 1, pp. 1-149
Closed Access
Effects of sacubitril/valsartan on cardiac reverse remodeling and cardiac resynchronization in patients with acute myocardial infarction
Pei Yang, Xiao‐Kang Li, Lijin Wang, et al.
Frontiers in Cardiovascular Medicine (2023) Vol. 9
Open Access | Times Cited: 9
Comparison of the effects of angiotensin receptor–neprilysin inhibitors and thiazide diuretic/renin–angiotensin system inhibitor combination therapy in hypertensive patients: a retrospective cohort study
Ryunosuke Mitsuno, Kiyotaka Uchiyama, Takashin Nakayama, et al.
Journal of Human Hypertension (2023) Vol. 37, Iss. 12, pp. 1049-1055
Closed Access | Times Cited: 7
The Application of Angiotensin Receptor Neprilysin Inhibitor in Cardiovascular Diseases: A Bibliometric Review From 2000 to 2022
Xia Xu, Yumeng Li, Shuqing Shi, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 8
Sacubitril/valsartan reversal of left ventricular remodeling is associated with improved hemodynamics in resistant hypertension
Lixue Song, Hongrui Yang, Ning Xiang, et al.
Hellenic Journal of Cardiology (2024)
Open Access | Times Cited: 1
Plasma renin activity as a marker for predicting the antihypertensive effect of switching to sacubitril/valsartan in treated hypertensive patients: Usefulness in daily clinical practice
Takeshi Horio, Yoshio Iwashima, Minoru Yoshiyama, et al.
Journal of Clinical Hypertension (2024) Vol. 26, Iss. 10, pp. 1196-1200
Open Access | Times Cited: 1
Cross talk on therapeutic strategies: natriuretic peptides and inhibiting neprilysin in hypertension management
Maya K Jangid, Gaurav Doshi
Hypertension Research (2024) Vol. 48, Iss. 1, pp. 284-300
Closed Access | Times Cited: 1
Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting
Xinyue Dong, Xiaoning He, Jing Wu
PharmacoEconomics (2022) Vol. 40, Iss. 12, pp. 1187-1205
Closed Access | Times Cited: 4
Comparison of sacubitril/valsartan with olmesartan for hypertension: A meta-analysis of randomized controlled trials
Ying Sun, Hua Yang
Medicine (2024) Vol. 103, Iss. 14, pp. e37501-e37501
Open Access
Clinical Benefit of Sacubitril/Valsartan for Hypertensive Patients in Daily Practice and Predictors of Its Antihypertensive Effect
Takeshi Horio, Yoshio Iwashima, Minoru Yoshiyama, et al.
Circulation Reports (2024) Vol. 6, Iss. 7, pp. 248-254
Open Access
Efficacy of sacubitril/valsartan versus valsartan in patients with arterial hypertension
A. S. Ryazanov, Л. В. Мельникова, M.V. Makarovskaya, et al.
Arterial’naya Gipertenziya (Arterial Hypertension) (2024) Vol. 30, Iss. 2, pp. 198-206
Open Access
Transformation of sartan blood pressure regulators by ferrate(VI) and its activation systems: Kinetics and mechanisms
Shuiqin Shi, Q. Zeng, Junmei Yan, et al.
Separation and Purification Technology (2024), pp. 129781-129781
Closed Access
Efficacy of sacubitril–valsartan vs. angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in preventing atrial fibrillation recurrence after catheter ablation: a systematic review and meta-analysis
Fernando Baía Bezerra, Luis Eduardo Rodrigues Sobreira, Vitor Kendi Tsuchiya Sano, et al.
Herz (2024)
Closed Access
Page 1 - Next Page

Scroll to top